Business
Clene to Present at H.C. Wainwright’s 5th Annual Neuro Perspectives Virtual Conference
SALT LAKE CITY, June 24, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene
About this update from Clene Inc.
SALT LAKE CITY , June 24, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc. , a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at H.C. Wainwright’s 5th Annual Neuro Perspectives Virtual Conference and host 1x1 investor meetings. Date: June 27, 2024 Time of Presentation: Available upon demand Format: Fireside Chat 1x1 Meetings: Please contact your HCW representative A webcast of the presentation will be available on the “ Events ” section of the Clene website. Alternatively, one can register online to view the webcast here . About Clene Clene Inc. , (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc. , is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8 is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah , with R&D and manufacturing operations in Maryland . For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn . Contacts: Media Contact Ignacio Guerrero-Ros , Ph.D., or David Schull Russo Partners, LLC I [email protected] [email protected] (858) 717-2310 Investor Contact Kevin Gardner LifeSci Advisors [email protected] 617-283-2856 Source: Clene Inc.